AstraZeneca’s diabetes drug study shows benefit in adolescents
June 25, 2021; 12:44 PM EDT
(Reuters) – AstraZeneca Plc’s (AZN.L) diabetes drug significantly reduced blood sugar levels in adolescents aged 10–17 with type 2 diabetes in a late-stage study, the UK-based drugmaker said on Friday.
In type 2 diabetes, the body cannot properly use or make enough of the hormone insulin to convert blood sugar into energy.
In the study, patients who received once-weekly dose of exenatide, sold as Bydureon by AstraZeneca, showed significantly reduced levels of HbA1c – a measure of average blood sugar – from baseline at 24 weeks compared to placebo.
Exenatide is already approved in the United States for adult patients with type 2 diabetes.
Data from the study was presented at the 2021 American Diabetes Association (ADA) Virtual 81st Scientific Sessions.
Our Standards: The Thomson Reuters Trust Principles.